International Assets Investment Management LLC cut its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 36.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,690 shares of the medical technology company’s stock after selling 5,601 shares during the period. International Assets Investment Management LLC’s holdings in Medtronic were worth $825,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in MDT. Brian Low Financial Group LLC raised its holdings in Medtronic by 5.0% during the third quarter. Brian Low Financial Group LLC now owns 20,825 shares of the medical technology company’s stock worth $1,797,000 after purchasing an additional 992 shares in the last quarter. Glenview Trust Co increased its position in shares of Medtronic by 1.3% during the 3rd quarter. Glenview Trust Co now owns 48,703 shares of the medical technology company’s stock valued at $4,203,000 after purchasing an additional 637 shares during the period. Parcion Private Wealth LLC increased its position in shares of Medtronic by 54.1% during the 3rd quarter. Parcion Private Wealth LLC now owns 7,988 shares of the medical technology company’s stock valued at $689,000 after purchasing an additional 2,805 shares during the period. Soltis Investment Advisors LLC raised its stake in shares of Medtronic by 26.5% in the 3rd quarter. Soltis Investment Advisors LLC now owns 167,746 shares of the medical technology company’s stock worth $14,475,000 after buying an additional 35,100 shares in the last quarter. Finally, United Asset Strategies Inc. raised its stake in shares of Medtronic by 3.8% in the 3rd quarter. United Asset Strategies Inc. now owns 9,466 shares of the medical technology company’s stock worth $817,000 after buying an additional 345 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.
Medtronic Stock Performance
Shares of NYSE MDT opened at $105.02 on Thursday. The stock’s fifty day simple moving average is $92.21 and its 200 day simple moving average is $88.39. The stock has a market capitalization of $134.34 billion, a price-to-earnings ratio of 17.29, a PEG ratio of 2.31 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 52-week low of $73.31 and a 52-week high of $106.33.
Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The company had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. During the same period last year, the company posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.
Medtronic Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic’s payout ratio is 70.94%.
Insider Activity
In other news, EVP Harry Kiil sold 1,483 shares of the firm’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Geoffrey Martha sold 50,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the sale, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. This trade represents a 15.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 61,903 shares of company stock worth $5,889,203 over the last quarter. Corporate insiders own 0.27% of the company’s stock.
Medtronic News Summary
Here are the key news stories impacting Medtronic this week:
- Positive Sentiment: Medtronic reported that the SPYRAL AFFIRM real-world study found statistically significant, clinically meaningful blood-pressure reductions six months after treatment with its Symplicity Spyral system. Reductions were seen in office, home, and 24-hour ambulatory readings, without an increase in antihypertensive medications. The findings could strengthen the case for the procedure and support future adoption, though the announcement does not quantify potential sales impact. Article
- Neutral Sentiment: Medtronic and the Michael J. Fox Foundation launched an educational initiative to help people with Parkinson’s and caregivers understand deep brain stimulation (DBS). It may raise awareness of an established treatment, but no new product, clinical result, or revenue outlook was announced. Article
- Neutral Sentiment: The company said it will release fiscal Q2 2027 results on November 24. This is a scheduling announcement, with no new financial guidance or operating results. Article
- Negative Sentiment: A report said ETFs were net sellers of MDT, with $110.6 million in outflows on Friday. This is a short-term flow signal and may not indicate a lasting change in investor views. Article
- Negative Sentiment: An analyst roundup cited a consensus price target of $102.88, below the $105.02 reference price in the supplied market data, suggesting limited upside at that level. Article
Analyst Ratings Changes
Several equities research analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Saturday, October 31st. Stifel Nicolaus lifted their price objective on shares of Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research note on Wednesday, September 2nd. Mizuho set a $115.00 target price on shares of Medtronic in a report on Wednesday, September 2nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $92.00 target price on shares of Medtronic in a research note on Thursday, September 3rd. Eighteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and a consensus price target of $102.88.
Check Out Our Latest Stock Analysis on MDT
About Medtronic
Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.
The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.
Featured Articles
- Five stocks we like better than Medtronic
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
